Dr Boni received her MD with honors cum laude in 2005 from the Catholic University of Rome, Italy. In 2009, she completed her medical training in oncology at the “Agostino Gemelli” University Hospital in Rome, Italy. Her interest in clinical research led her to join as Clinical Researcher, the Pharmacogenomic lab at the Center for Applied Medical Research (CIMA), in Pamplona, Spain, working on translational oncology, mainly focused on predictive biomarkers discovery and precision medicine. She subsequently earned her PhD in medicine from the University of Navarra in 2011 for her work entitled “Role of miRNAs as predictive biomarkers in metastatic colorectal cancer” with honors cum laude. In 2013, she joined the ECCO-AACR-EORTC-ESMO workshop on methods in clinical cancer research (Flims), Switzerland.
From 2011, Dr Boni focused her work on the design and clinical early drug development leading several clinical trials. She has participated as Principal Investigator and co-investigator in more than 200 phase ½ studies, including First-in-Human, immunotherapy trials, combinations of targeted therapies and immunotherapies, biomarker-driven trials and trials in molecularly selected populations with special emphasis on breast cancer, gynecological tumors and melanoma. She has pioneered the development of new anticancer drugs now approved such as larotrectinib, selpercatinib, dostarlimab, lurbinectedin. Dr Boni’s research interests include the Phase I and early drug development of new anticancer agents as well as molecular genetic targets, immunotherapies, antibody drug conjugates, epigenetics and precision medicine for cancer therapy.
She authored and co-authored several papers in peer-reviewed journals including New England Journal of Medicine and Nature as well as of communications at different national and international congresses. She served as Faculty Member for the American Society of Clinical Oncology and as Clinical Associated Professor of Medicine at the European University, Madrid. She has participated in setting up the Spanish Molecular Tumor Board at GETTHI and in her institution where she is coordinating the precision medicine program centered on molecular analysis of patients’ tumors and molecular prescreening including circulating DNA and expression profiling to select the best anti-cancer therapy for any single patient and for better delivering precision medicine in clinical practice. Dr. Boni is member of the American Society of Clinical Oncology and of the European Society of Medical Oncology. She serves as an ad-hoc reviewer of various oncology journals.